Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Reddit Inc (RDDT) vs Viatris Inc (VTRS) Price & Performance

Reddit IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Reddit Inc vs Viatris Inc — how do they compare? Reddit Inc trades at $159.84 (market cap $30.10B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Reddit Inc is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while Reddit Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Reddit Inc for 26 Days and Viatris Inc for 57 Days on average.

RDDTVTRS
Market Cap
$30.10B$20.03B
Volume
4,560,44014,109,977
Sector
MediaHealth
52-Week High
$258.93$18.27
52-Week Low
$121.84$9.74
Typical Hold Time
26 Days57 Days
Enterprise Value
$27.34B$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Reddit Inc

Reddit (RDDT) trades at $159.84, up 4.63% today, showing strong momentum after three consecutive quarterly earnings beats. The stock maintains a bullish technical outlook with support at $154 and resistance at $160. Fundamentally, the company demonstrates exceptional profitability with 91.44% gross margins and 31.35% net income margins, while revenue growth accelerated to $2.8 billion in 2026. Recent developments include a strategic partnership with Zefr for AI-powered advertising solutions and expanding international revenues by 84%.

The investment outlook remains positive with 65.5% analyst buy ratings and a $202.52 consensus price target representing 27% upside potential. Key opportunities include continued AI data licensing growth and international expansion, while risks involve competitive pressure from Meta and regulatory concerns. The stock's premium valuation at 36.4x P/E requires sustained execution to justify current levels.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.

The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RDDT
43% Buy57% Sell
Avg holding period · 26 Days
VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About Reddit Inc

Reddit Inc. operates a vast network of online communities organized around various interests, known as 'subreddits'. Functioning as a hybrid of a social media platform and a discussion forum, the company generates revenue primarily through advertising and premium subscriptions. Reddit is a major hub for user-generated content, trending news, and viral discussions, and it is a key player in the digital advertising and social media landscape.

Read more on RDDT →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →